SCHEMBL2116839

SCHEMBL2116839

COc1ccc(-c2ccc(C)c(NS(=O)(=O)c3ccnc(OC)c3)c2)nc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.48
ALDH1A1 P00352 2/20 0.43
TSHR P16473 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
CYP2C9 P11712 1/20 0.43
KDM4E B2RXH2 1/20 0.43
FFAR4 Q5NUL3 2/20 0.42
KEAP1 Q14145 1/20 0.41
PIK3CA P42336 1/20 0.40
MTOR P42345 1/20 0.40
BRD4 O60885 1/20 0.39
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA3 P34903 1/20 0.39
NAMPT P43490 1/20 0.39
TP53 P04637 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2119248 0.88 MAPT (0.48) MAPTALDH1A1TSHRNPSR1CYP2C9
SCHEMBL2117126 0.87 MAPT (0.46) MAPTALDH1A1TSHRNPSR1CYP2C9
SCHEMBL2121929 0.86 MAPT (0.51) MAPTALDH1A1TSHRNPSR1CYP2C9
SCHEMBL2120392 0.86 PIK3CA (0.43) MAPTPIK3CAMTOR
SCHEMBL2118441 0.83 MAPT (0.43) MAPTALDH1A1TSHRNPSR1CYP2C9
SCHEMBL2120161 0.83 MAPT (0.54) MAPTALDH1A1TSHRNPSR1CYP2C9
SCHEMBL2119462 0.83 LMNA (0.55) MAPTALDH1A1TSHRNPSR1CYP2C9
SCHEMBL2117841 0.83 MAPT (0.54) MAPTALDH1A1TSHRNPSR1CYP2C9
SCHEMBL2119228 0.82 MAPT (0.54) MAPTALDH1A1TSHRNPSR1CYP2C9
SCHEMBL2118122 0.82 MAPT (0.48) MAPTALDH1A1TSHRNPSR1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1A, HIF1AN, EGLN3 MAPT 4747/4885ALDH1A1 1063/4885TSHR 1314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.